MB
MPM BioImpact Portfolio holdings
AUM
$577M
This Quarter Return
+18.1%
1 Year Return
+8.33%
3 Year Return
+241.63%
5 Year Return
+127.38%
10 Year Return
–
AUM
$422M
AUM Growth
+$422M
(+17%)
Cap. Flow
+$59.4M
Cap. Flow
% of AUM
14.06%
Top 10 Holdings %
Top 10 Hldgs %
68.75%
Holding
41
New
4
Increased
4
Reduced
14
Closed
3
Top Buys
| 1 |
VERV
Verve Therapeutics
VERV
|
$21.8M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$18.8M |
| 3 |
Regenxbio
RGNX
|
$16.4M |
| 4 |
Iovance Biotherapeutics
IOVA
|
$4.79M |
| 5 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$4.61M |
Top Sells
| 1 |
EPZM
Epizyme, Inc
EPZM
|
$5.03M |
| 2 |
Mirum Pharmaceuticals
MIRM
|
$4.02M |
| 3 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$2.53M |
| 4 |
NeoGenomics
NEO
|
$1.11M |
| 5 |
Amicus Therapeutics
FOLD
|
$1.07M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cullinan Oncology
CGEM
$445M
| $98.1M | 23.22% | 7,648,268 | – | – |
|
2
iTeos Therapeutics
ITOS
| $33.3M | 7.88% | 1,745,943 | – | – |
|
|
INBX
3
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $23M | 5.44% | 1,279,995 +256,670 | +25% | +$4.61M |
|
|
VERV
4
DELISTED
Verve Therapeutics
VERV
| $21.8M | 5.17% | +635,792 | New | +$21.8M |
|
5
Intellia Therapeutics
NTLA
$1.22B
| $21M | 4.96% | 374,409 +75,000 | +25% | +$4.2M |
|
6
Repare Therapeutics
RPTX
$71.7M
| $19.9M | 4.71% | 1,639,849 | – | – |
|
7
Geron
GERN
$893M
| $19.7M | 4.67% | 8,422,582 -12,409 | -0.1% | -$29K |
|
|
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $18.8M | 4.46% | +1,050,000 | New | +$18.8M |
|
9
Merus
MRUS
$4.98B
| $18.4M | 4.36% | 918,310 -1,172 | -0.1% | -$23.5K |
|
|
10
Regenxbio
RGNX
$451M
| $16.4M | 3.88% | +619,083 | New | +$16.4M |
|
|
11
Iovance Biotherapeutics
IOVA
$807M
| $16.3M | 3.86% | 1,700,000 +500,000 | +42% | +$4.79M |
|
12
Werewolf Therapeutics
HOWL
$59.9M
| $10.8M | 2.55% | 2,388,011 | – | – |
|
|
GTHX
13
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $10.7M | 2.53% | 856,798 | – | – |
|
14
Cytokinetics
CYTK
$4.23B
| $9.36M | 2.22% | 193,205 -1,041 | -0.5% | -$50.4K |
|
15
BioCryst Pharmaceuticals
BCRX
$1.74B
| $7.63M | 1.81% | 605,663 -33,426 | -5% | -$421K |
|
16
Crinetics Pharmaceuticals
CRNX
$2.92B
| $7.16M | 1.7% | 364,710 -1,966 | -0.5% | -$38.6K |
|
17
Travere Therapeutics
TVTX
$1.56B
| $6.81M | 1.61% | 276,460 -1,490 | -0.5% | -$36.7K |
|
18
Y-mAbs Therapeutics
YMAB
$388M
| $6.4M | 1.52% | 443,702 | – | – |
|
|
TCRR
19
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $6.07M | 1.44% | 3,370,982 | – | – |
|
20
Harmony Biosciences
HRMY
$2.12B
| $6.06M | 1.43% | 136,780 -737 | -0.5% | -$32.6K |
|
21
Arcutis Biotherapeutics
ARQT
$1.86B
| $4.92M | 1.16% | 257,185 -1,315 | -0.5% | -$25.1K |
|
|
RETA
22
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $4.5M | 1.07% | 179,058 -942 | -0.5% | -$23.7K |
|
|
23
Amicus Therapeutics
FOLD
$2.34B
| $4.1M | 0.97% | 392,946 -102,657 | -21% | -$1.07M |
|
|
PRVB
24
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $3.33M | 0.79% | 740,344 +147,909 | +25% | +$666K |
|
|
HARP
25
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $3.1M | 0.73% | 3,196,707 | – | – |
|